<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116995</url>
  </required_header>
  <id_info>
    <org_study_id>SUM001</org_study_id>
    <nct_id>NCT05116995</nct_id>
  </id_info>
  <brief_title>Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients</brief_title>
  <acronym>DEFINE CCS</acronym>
  <official_title>Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients: Define CCS Study, a Prospective Randomized Crossover Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be comparing the effects of two different drug treatment strategies,&#xD;
      in patients with history of a heart attack, on different markers of bleeding and clotting&#xD;
      risk. Both treatment strategies are already approved for the indication of improving outcomes&#xD;
      in high-risk patients with history of heart attack.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll patients with coronary disease &gt;1 year after an acute coronary&#xD;
      syndrome. Subjects will be randomized to one of two treatment plans. One plan the participant&#xD;
      will take ticagrelor for one week, then take two weeks off with no drug (washout period),&#xD;
      then one week of rivaroxaban. The other plan will be reverse order where the participant will&#xD;
      take rivaroxaban for one week, then two weeks off(washout period), then one week of&#xD;
      ticagrelor. Study drugs will be provided to participants at the start of each treatment&#xD;
      period. Bleeding time will be determined and blood samples will be taken at four timepoints&#xD;
      (baseline, post first drug, pre second drug, and post second drug) to measure complete blood&#xD;
      count, CRP, and fibrin clot assessment. These are surrogate markers for safety (bleeding) and&#xD;
      efficacy (increased thrombotic risk)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Treatment #1 for one week then on Day 21 they enter Treatment #2 for 1 week.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Study personnel performing bleeding time and laboratory staff will be blinded to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding time</measure>
    <time_frame>7 days</time_frame>
    <description>The primary objective is to determine the differential effect of rivaroxaban and ticagrelor on bleeding time as a surrogate marker for bleeding tendency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differential effects on inflammatory markers (white cell count and CRP)</measure>
    <time_frame>7 days</time_frame>
    <description>These will be measured from blood draws</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential effects on fibrin clot lysis time</measure>
    <time_frame>7 days</time_frame>
    <description>This will be measured from blood draws</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thrombosis</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>rivaroxaban 2.5 mg twice a day for 7 days</description>
    <arm_group_label>Rivaroxaban first</arm_group_label>
    <arm_group_label>Ticagrelor first</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 60 mg twice a day for 7 days</description>
    <arm_group_label>Rivaroxaban first</arm_group_label>
    <arm_group_label>Ticagrelor first</arm_group_label>
    <other_name>brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic coronary syndrome (at least 1 year after having a myocardial&#xD;
             infarction) on aspirin monotherapy will be eligible for this study. They have to have&#xD;
             at least one of these additional risk factors:&#xD;
&#xD;
               1. Diffuse coronary artery disease.&#xD;
&#xD;
               2. Peripheral vascular disease&#xD;
&#xD;
               3. Diabetes&#xD;
&#xD;
               4. Chronic kidney disease (eGFR&lt;60 ml/unit/1.73 m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to either rivaroxaban or ticagrelor&#xD;
&#xD;
          -  Requirement for anticoagulation or P2Y12 inhibitor therapy&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 10 g/dL)&#xD;
&#xD;
          -  Severe renal impairment (eGFR &lt; 30 ml/unit/1.73 m2)&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Significant liver impairment resulting in deranged clotting parameters&#xD;
&#xD;
          -  Any history of intracranial hemorrhage&#xD;
&#xD;
          -  Stroke within 6 months&#xD;
&#xD;
          -  History of gastrointestinal bleed within 6 months&#xD;
&#xD;
          -  Major surgery within 1 month&#xD;
&#xD;
          -  Patients with inflammatory conditions&#xD;
&#xD;
          -  Concomitant treatment with immunosuppressive therapy, inhibitors or inducers of P&#xD;
             glycoprotein or CYP3A4 enzymes (eg. azole antifungals, ritonavir, erythromycin,&#xD;
             clarithromycin, rifampicin)&#xD;
&#xD;
          -  Concomitant treatment with antidepressants (selective serotonin reuptake inhibitors,&#xD;
             serotonin and norepinephrine reuptake inhibitors)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to give written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nick J Bartlett, MSc</last_name>
    <phone>9024737417</phone>
    <email>nicholas.bartlett@nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wael Sumaya, PhD</last_name>
    <phone>9024735769</phone>
    <email>wael.sumaya@nshealth.ca</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Wael Sumaya</investigator_full_name>
    <investigator_title>Interventional Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

